Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

9. Malignant tumours other than HCC within 5 years prior to screening, except for malignancies with negligible risk of metastasis or death (eg, 5 year OS rate >90%), such as adequately treated in situ ...

Genetic testing revealed that she was positive for BRCA1, a genetic mutation that increases one’s risk of breast and ovarian ...

About 316,950 new cases of invasive breast cancer will be diagnosed in women. About 59,080 new cases of ductal carcinoma in situ (DCIS) will be diagnosed. About 42,170 women will die from breast ...

Background: Oesophageal squamous cell carcinoma (OSCC) has a very poor prognosis, which is largely due to late diagnosis. Successful early detection strategies will require identification of ...